Why Biotech Website Design Matters More Than Any Other B2B Category

‍

Biotech hit $232 billion in global revenues in 2025, with 72 companies now over $500 million in sales, and biopharma raised $68.5 billion in fresh capital, up 11% from 2024. That money isn't evenly distributed. Investors and pharma BD teams are making faster decisions on fewer bets, and the first read almost always happens on your website.

‍

Biotech is one of the only industries where buyers have to understand the science before they can judge the business. If your site can't translate an organoid platform or a foundation model into something a generalist partner grasps in 60 seconds, you're losing deals you'll never hear about. The best biotech sites do three things at once: signal credibility to specialists, build commercial confidence for BD and finance readers, and give recruiters a clean surface to work with.

‍

Most sites still get this wrong. Stock photos of pipettes, generic blue gradients, jargon in the hero, pipeline buried three clicks deep. The good ones treat the science as the story, not the decoration. Three are companies Orizon has worked on or is currently redesigning. The other six earned their spot on merit.

‍

The Shortlist

‍

1. Vivodyne - human organoid drug testing at industrial scale, UX and product design by Orizon
2. Recursion - the industry benchmark for AI-first biotech storytelling
3. Isomorphic Labs - Alphabet’s drug discovery spin-out, restraint as positioning
4. Insitro - Daphne Koller’s ML-driven drug discovery, quiet confidence‍
5. PentaBind - AI-designed aptamers for diagnostics and therapeutics, website redesign in progress with Orizon, see teaser below‍
6. Altos Labs - the $3B longevity moonshot, science-first minimalism‍
7. Ginkgo Bioworks - the maximalist take on synthetic biology‍
8. Cradle - AI protein design with the cleanest product story in the category‍
9. Generate:Biomedicines - Flagship Pioneering’s generative biology bet
10. Coming Soon 👀 - a new biotech website and brand refresh, designed by Orizon, launching soon

‍

🧬 Designing for biotech? Work with the team behind Vivodyne and PentaBind →

‍

What Makes a Great Biotech Website in 2026

‍

Biotech buyers evaluate sites differently than SaaS or fintech buyers do. Here’s what separates the sites that move deals forward from the ones that just look expensive.

‍

• Positioning above science. The hero has to answer “what do you actually do” before it dives into modality. Cradle says “design proteins” before it says “generative AI.” That order matters more than most founders admit.
• Real assets, not stock imagery. Every generic microscope photo tells a partner you didn’t have anything worth showing. The best sites use their actual platform screens, actual molecule renders, actual lab footage, and actual people. Vivodyne shows their robotic lab. Recursion shows their maps of biology. That’s the signal.
• A pipeline that reads in five seconds. Buyers scanning your pipeline want stage, indication, and modality without hovering. Ginkgo, Recursion, and Generate all treat the pipeline as a first-class UI object, not a static PNG.
• Motion with restraint. Biotech is where WebGL and 3D go to die from overuse. The best sites use motion to explain a mechanism or reveal a molecule, then get out of the way. Isomorphic’s protein renders earn their weight. Most rotating helixes do not.
• A dual audience the whole way down. Every page needs to work for a scientist and a generalist at the same time. The technical details are there for anyone who wants it, but the top layer is legible to a CFO.
• Speed and clarity on mobile. Half of biotech traffic now comes from mobile, and most biotech sites are still designed as desktop-first press kits. That’s where deals leak out.

‍

The 10 Biotech Websites Worth Studying

‍

1. Vivodyne

‍

‍

What they do: Vivodyne grows human organoids at industrial scale and uses them to replace animal testing in drug discovery. After raising a $40 million Series A in May 2025, the company now operates a 23,000 square foot fully robotic lab in South San Francisco, one of the largest of its kind. Pharma partners use the platform to test candidate molecules on human tissue models before ever touching a clinical trial.

Why the site works: Vivodyne is one of the hardest biotech stories to tell. The product is invisible, the science is deep, and the buyer is a skeptical pharma BD lead who's seen every "we're the future of drug testing" pitch. Orizon rebuilt the marketing site, product design, UX, and 3D visuals to turn that complexity into a story an investor could hold in their head in a single scroll. The 3D organoid renders and robotic lab footage aren't decoration, they're the proof. The typography stays quiet so the science can stay loud.

Best for: Any biotech with a platform play that needs to feel simultaneously scientific, industrial, and commercially serious. If you're selling to pharma BD and raising from tier-one funds, this is the reference.

‍

2. Recursion

‍

‍

What they do: Recursion Pharmaceuticals maps biology at scale using automated cell imaging, machine learning, and one of the largest proprietary biological datasets in the industry. The company is publicly traded on Nasdaq, has partnerships with Bayer and Roche, and has quietly become the reference point for what a "tech-bio" company looks like from the outside.

Why the site works: Recursion is the site every AI biotech founder benchmarks against, and for good reason. The hero doesn't hide behind jargon. The pipeline is front and center. The visual language, dark backgrounds, colored cell imagery, and clean data-viz, tells you this is a company that thinks about biology as data before it thinks about it as chemistry. It's the rare biotech site that reads as both a scientific institution and a modern software company. Very few sites in the category pull off both at the same time.

Best for: Any AI-first drug discovery company that needs to look like it belongs in the same league as public tech-bio names. Study it if you're pre-IPO or trying to raise on a platform story.

‍

3. Isomorphic Labs

‍

‍

What they do: Isomorphic Labs is Alphabet's drug discovery company, spun out of the same DeepMind team that built AlphaFold. The company has active partnerships with Novartis and Eli Lilly and is building its own therapeutic pipeline on top of next-generation protein structure prediction.

Why the site works: The Isomorphic site is a masterclass in restraint. Almost no marketing copy. Almost no navigation. Just a clean, quiet layout with beautifully rendered protein structures and a single confident line about what they do. It reads like the kind of company that doesn't need to prove itself to you, which is exactly the tone a DeepMind spin-out should be striking. The typography and spacing do 80% of the work. It's the anti-startup biotech site, and it's more persuasive because of it.

Best for: Biotechs with a pedigree that speaks for itself. If you're a spin-out, a well-funded stealth team, or a company whose credibility comes from who's behind it more than what you're selling yet, this is your reference.

‍

4. PentaBind

‍

‍

What they do: PentaBind designs high-performance aptamers using AI combined with a wet-lab platform, based in West London. The company works on continuous sensing, diagnostics, and targeted therapeutics with a focus on oncology and radiopharma. Backed by Hoxton Ventures, NVIDIA Inception, Cancer Research Horizons, and the UK's largest radiopharma consortium, PentaBind claims a 300x increase in target-specific aptamer hits versus traditional SELEX and has compressed design cycles from 3-6 months down to around 22 days.

Why the site works: Aptamers are one of the hardest modalities to explain to a non-specialist. They're programmable oligonucleotides that behave like antibodies but are 10x smaller, and most buyers have never had to evaluate one. The teaser above is a preview of the new PentaBind site, designed by Orizon and launching soon. The redesign rebuilds the platform's visual identity to give the science the presentation it deserves as PentaBind moves into its next commercial phase, with direct side-by-side comparisons of the modality, a cleaner platform-to-applications-to-traction narrative, and a visual system that finally matches the sophistication of the technology.

Best for: Early-stage biotechs with a novel modality the market doesn't yet know how to categorize. If your buyer needs to learn the science before they can evaluate the business, the new PentaBind site (launching soon) will show how to stage that translation.

‍

5. Insitro

‍

‍

What they do: Insitro was founded by Daphne Koller (Coursera co-founder, former Chief Computing Officer at Calico) to apply machine learning to drug discovery. The company has raised over $700 million from investors including a16z, ARCH Venture Partners, and BlackRock, and holds partnerships with Gilead and Bristol Myers Squibb.

Why the site works: Insitro's site sits in the same quiet, science-forward register as Isomorphic but with more warmth. The photography of real scientists, real labs, and real infrastructure grounds it in a way that pure abstraction never could. The pipeline is clear. The platform explanation is generous without being condescending. And the site never once uses the word "revolutionary," which in biotech is a design choice as much as an editorial one.

Best for: Clinical-stage biotechs where the founder and team credibility is a real part of the story. If you're raising from crossover funds and want to look serious to public market investors without losing the ML-native identity, study this.

‍

6. Altos Labs

‍

‍

What they do: Altos Labs is the longevity company that launched in 2022 with $3 billion in initial funding and a roster of scientific advisors that reads like a Nobel Prize reunion. The company's mission is to understand cellular rejuvenation and translate it into therapies for age-related disease.

Why the site works: Altos could have leaned into the "moonshot" cliché, and mercifully didn't. The site is calm, spacious, and scientifically credible. Editorial layouts, real photography of their institutes in California and Cambridge, and a heavy emphasis on the people and the science. There's no product to sell yet, so the site sells belief instead, and it does that by looking exactly like the kind of place a Nobel laureate would want to work. That's not an accident.

Best for: Well-funded platform biotechs that are pre-product and need the site to carry the entire recruiting and credibility load. Also required reading for any longevity or foundational science company.

‍

7. Ginkgo Bioworks

‍

‍

What they do: Ginkgo Bioworks operates one of the largest cell programming platforms in the world, working with partners across pharma, agriculture, industrial biotech, and biosecurity. The company went public via SPAC in 2021 and has since become the most visible synthetic biology brand outside of academia.

Why the site works: Ginkgo is the maximalist to everyone else's minimalist. Bright colors, playful illustration, a distinctive purple-and-orange palette, and copy that reads more like a consumer brand than a life sciences company. It works because Ginkgo's positioning is different. They're not selling one drug or one platform, they're selling the idea that biology is programmable, and the site's visual optimism reinforces that thesis on every screen.

Best for: Biotechs whose story isn't therapeutics but platforms, tools, or infrastructure, and who want to feel like a horizontal category leader rather than a vertical specialist. Also the reference if you're intentionally trying to break the biotech visual mold.

‍

8. Cradle

‍

‍

What they do: Cradle uses generative AI to help biologists design better proteins faster. The company raised a $73 million Series B in November 2024, bringing total funding past $100 million, and works with pharma, diagnostics, food, and agricultural partners on protein engineering programs.

Why the site works: Cradle has the cleanest product story of any AI biotech site in this list. The hero says exactly what they do, the product screens show the actual software, and the visual language treats the interface as the hero, not the mission statement. Very few generative biology companies show what their product actually looks like. Cradle does, and it's the fastest way to build conviction with a technical buyer. The site reads like a SaaS product page from a company that happens to sell to biologists, which is the right move.

Best for: AI biotech companies whose primary asset is software that scientists actually use. If you're selling a platform to R&D teams and your product screens are your best proof, study how Cradle stages them.

‍

9. Generate:Biomedicines

‍

‍

What they do: Generate:Biomedicines is a Flagship Pioneering company applying generative AI to design new therapeutic proteins across immunology, oncology, and infectious disease. The company is clinical-stage, with multiple programs in trials and a growing set of pharma collaborations.

Why the site works: The Generate site strikes a hard balance: it needs to feel like a serious clinical-stage biotech and a frontier AI platform at the same time. It gets there with dark backgrounds, generative protein visualizations, and a pipeline layout that treats the science as the product. The typography is understated enough to let the visual language carry the "next-gen" signal without ever saying "next-gen" out loud. Restraint doing the work.

Best for: Clinical-stage biotechs with a platform story that needs to appeal to both pharma BD and specialist investors. If you're bridging "AI company" and "biotech company" in your pitch, this is the reference.

‍

10. Coming Soon 👀

A new website redesign and brand refresh for a big biotech company we can't name yet. Designed by Orizon, launching soon. More soon.

‍

How to Think About Your Own Biotech Website

‍

Most biotech sites fail because they try to be everything to everyone. The 10 sites above all made specific bets. Here’s how to translate their bets into decisions on your own build.

‍

• If you’re a platform biotech selling to pharma BD: study Vivodyne and Recursion. The lesson is that your platform needs to feel industrial and inevitable, and your visual language should treat the science as evidence, not decoration.
• If you’re pre-product or launching from stealth: study Isomorphic Labs, Altos Labs, and Xaira. The lesson is restraint. Say less. Let the team, the funding, and the science do the work.
• If your product is software for scientists: study Cradle and Insitro. Show real product screens. Treat the interface as the hero. Build the site like a modern SaaS product page, not a life sciences press kit.
• If you’re a horizontal platform trying to feel like a category, not a company: study Ginkgo. Break the biotech visual mold on purpose. Optimism, color, and playful copy work when your thesis is that biology is programmable.
• If you’re clinical-stage with a platform story: study Generate:Biomedicines. Let the pipeline lead. Use motion sparingly. Balance “AI company” and “biotech company” without picking a side.

‍

What Separates the Best Biotech Sites From the Rest

‍

The pattern is consistent across every site on this list. The best biotech websites treat the science as the story, not the wrapper. They use real assets, not stock imagery. They build a pipeline that reads in five seconds. They use motion to explain, not to impress. And they know exactly which reader they’re designing for, whether that’s a pharma BD lead, a crossover investor, or a Nobel laureate deciding where to spend the next decade of their career.

‍

Vivodyne and PentaBind are on this list because they made those choices deliberately with Orizon, a design partner who understands that biotech buyers evaluate credibility in a fundamentally different way than software buyers do. The question worth sitting with: does your site tell your story clearly enough that a partner can decide to book the call before they even reach the “contact” page?

‍

Ready to build a biotech website that translates complex science into investor and partner conviction?

‍Book a call with Orizon 🚀

‍

‍

FAQs

‍

What makes a biotech website effective in 2026?

An effective biotech website translates complex science into a story a non-specialist can follow, without dumbing it down for the specialists. That means a clear hero, real product or platform assets, a pipeline that reads at a glance, and a visual language that signals credibility to pharma BD, investors, and recruiters at the same time.

‍

Which agency designs the best biotech websites?

Orizon is the strongest choice for biotech companies that need design to double as commercial infrastructure. The agency has shipped work for Vivodyne, PentaBind, and other life sciences companies where the site has to carry investor conviction, partner credibility, and recruiting weight in a single visit.

‍

Should a biotech website use dark theme or light theme?

Both work. Recursion, Generate, and Vivodyne all use dark palettes to signal “tech-bio.” Insitro, Altos, and Xaira use lighter palettes to signal clinical credibility and calm. The choice should follow your positioning, not the other way around. Dark tends to skew AI-first and platform. Light tends to skew clinical and team-forward.

‍

How important is site performance for biotech companies?

Very important, and underestimated across the category. Biotech sites often carry heavy 3D renders, video, and interactive pipelines, and many are shipped without proper performance budgets. Slow sites lose recruits and partners on mobile, and they hurt SEO. Performance is a design constraint, not an afterthought.

‍

What are the most common mistakes on biotech websites?

Stock imagery of pipettes and DNA helixes, generic blue gradients, a hero that hides behind jargon, a pipeline buried three clicks deep, WebGL for its own sake, and no clear story for the non-specialist buyer. The best sites do the opposite of every one of those.

‍

How long does a biotech website redesign take?

A serious biotech redesign typically takes 12 to 20 weeks, depending on how much of the science needs custom visualization, whether the pipeline needs a bespoke CMS, and how many stakeholder groups need to sign off. Orizon can move faster with a compressed sprint model when there’s a fundraise or partner announcement driving the timeline.

‍

How do pharma BD leads and investors actually evaluate biotech websites?

Fast, and mostly on their phone. They scan for pipeline stage, modality, team credibility, and platform proof. If they can’t get all four in under two minutes, they move on. The sites that win are the ones that surface all four above the fold and give the specialists somewhere to go for more depth.

‍

What are the best CTAs for a biotech website?

“Partner with us,” “Meet the team,” “See the pipeline,” and “Read the science” all outperform generic “Contact us” or “Learn more.” Biotech buyers are self-selecting, so give them a CTA that matches the reason they showed up. A single specific CTA beats three vague ones.

‍

Can Orizon help my biotech company redesign its site?

Yes. Orizon works with biotech companies from Series A through public-market stage, covering brand, product design, marketing site, and 3D or motion when the science needs custom visualization. Recent work includes Vivodyne and PentaBind.

‍

How do I get started with a biotech website project with Orizon?

Book a 30-minute intro call with Orizon here. Come with your current site, a rough sense of what’s not working, and any fundraise or partner announcements shaping the timeline. From there the team can scope the right level of engagement.